edaravone has been researched along with Heart Failure in 2 studies
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Edaravone suppressed plasma MCP-1, improved left ventricular ejection fraction, and reduced rehospitalization due to heart failure." | 9.14 | Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction. ( Chitose, T; Fukuda, M; Kaikita, K; Nagata, T; Nagayoshi, Y; Nakamura, Y; Nako, H; Ogawa, H; Ogura, Y; Ohba, K; Shimomura, H; Soejima, H; Sugiyama, S; Tsujita, K; Yamada, Y; Yamaguchi, M; Yamashita, T, 2009) |
| "Edaravone suppressed plasma MCP-1, improved left ventricular ejection fraction, and reduced rehospitalization due to heart failure." | 5.14 | Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction. ( Chitose, T; Fukuda, M; Kaikita, K; Nagata, T; Nagayoshi, Y; Nakamura, Y; Nako, H; Ogawa, H; Ogura, Y; Ohba, K; Shimomura, H; Soejima, H; Sugiyama, S; Tsujita, K; Yamada, Y; Yamaguchi, M; Yamashita, T, 2009) |
| "During the development of heart failure, edaravone ameliorated the defective interdomain interaction of the RyR2." | 3.73 | Correction of defective interdomain interaction within ryanodine receptor by antioxidant is a new therapeutic strategy against heart failure. ( Doi, M; Ikeda, Y; Ikemoto, N; Kobayashi, S; Matsuzaki, M; Mochizuki, M; Noma, T; Oda, T; Ohkusa, T; Okuda, S; Tateishi, H; Tokuhisa, T; Yamamoto, T; Yano, M, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakamura, Y | 1 |
| Yamada, Y | 1 |
| Shimomura, H | 1 |
| Nagayoshi, Y | 1 |
| Tsujita, K | 1 |
| Yamashita, T | 1 |
| Fukuda, M | 1 |
| Ohba, K | 1 |
| Nako, H | 1 |
| Ogura, Y | 1 |
| Chitose, T | 1 |
| Yamaguchi, M | 1 |
| Nagata, T | 1 |
| Soejima, H | 1 |
| Kaikita, K | 1 |
| Sugiyama, S | 1 |
| Ogawa, H | 1 |
| Yano, M | 1 |
| Okuda, S | 1 |
| Oda, T | 1 |
| Tokuhisa, T | 1 |
| Tateishi, H | 1 |
| Mochizuki, M | 1 |
| Noma, T | 1 |
| Doi, M | 1 |
| Kobayashi, S | 1 |
| Yamamoto, T | 1 |
| Ikeda, Y | 1 |
| Ohkusa, T | 1 |
| Ikemoto, N | 1 |
| Matsuzaki, M | 1 |
1 trial available for edaravone and Heart Failure
| Article | Year |
|---|---|
Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Antipyrine; Biomarkers; Chemokine CCL2; Edaravone; Female; Fre | 2009 |
1 other study available for edaravone and Heart Failure
| Article | Year |
|---|---|
Correction of defective interdomain interaction within ryanodine receptor by antioxidant is a new therapeutic strategy against heart failure.
Topics: Animals; Antioxidants; Antipyrine; Calcium; Cardiac Pacing, Artificial; Dogs; Edaravone; Heart Failu | 2005 |